{"filing":{"accession_number":"0001140361-26-029291","cik":"0001743881","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ef20078442_form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126029291/ef20078442_form8k.htm"},"events":[{"id":19610,"run_id":17644,"accession_number":"0001140361-26-029291","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The FDA's acceptance of an NDA for encaleret in ADH1 is a material regulatory milestone for a biopharmaceutical company. While this is not a traditional earnings release, restatement, or executive change, it represents a significant operational and regulatory achievement—the company describes it as \"a major step forward\" and a \"powerful validation\" enabling potential launch of a \"blockbuster opportunity.\" The PDUFA target action date of May 8, 2027 and the company's stated preparedness to launch upon approval would materially affect investor assessment of the registrant's pipeline and commercial prospects. This is best classified as operational_other because it is a regulatory/clinical milestone that is clearly operational in nature but does not fit the specific categories of earnings_release, ma_activity, or other named types.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18746,"accession_number":"0001140361-26-029291","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The FDA's acceptance of an NDA for encaleret in ADH1 is a material regulatory milestone for a biopharmaceutical company. While this is not a traditional earnings release, restatement, or executive change, it represents a significant operational and regulatory achievement—the company describes it as \"a major step forward\" and a \"powerful validation\" enabling potential launch of a \"blockbuster opportunity.\" The PDUFA target action date of May 8, 2027 and the company's stated preparedness to launch upon approval would materially affect investor assessment of the registrant's pipeline and commercial prospects. This is best classified as operational_other because it is a regulatory/clinical milestone that is clearly operational in nature but does not fit the specific categories of earnings_release, ma_activity, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:36:00.937596+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18746,"accession_number":"0001140361-26-029291","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The FDA's acceptance of an NDA for encaleret in ADH1 is a material regulatory milestone for a biopharmaceutical company. While this is not a traditional earnings release, restatement, or executive change, it represents a significant operational and regulatory achievement—the company describes it as \"a major step forward\" and a \"powerful validation\" enabling potential launch of a \"blockbuster opportunity.\" The PDUFA target action date of May 8, 2027 and the company's stated preparedness to launch upon approval would materially affect investor assessment of the registrant's pipeline and commercial prospects. This is best classified as operational_other because it is a regulatory/clinical milestone that is clearly operational in nature but does not fit the specific categories of earnings_release, ma_activity, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:36:00.937596+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-07-22"}]}